Zhiqin Xie
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 26, 2024
A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: January 16, 2024
Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: November 10, 2022
Current Trends and Research Hotspots in Pancreatic Stellate Cells: A Bibliometric Study.
Journal: Frontiers in oncology
Published: March 15, 2022
Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma.
Journal: Frontiers in oncology
Published: February 08, 2022
CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.
Journal: Cell death & disease
Published: January 02, 2022
GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
Journal: Journal of advanced research
Published: December 18, 2021
SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression.
Journal: Journal of hepatocellular carcinoma
Published: November 30, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026